CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions

Multiple Sclerosis

Volumn 14, Issue 6, 2008, Pages 728-733

  Trebst, Corinna ^a   Konig F ^b   Ransohoff, R M ^c   Bruck W ^b   Stangel, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemokine receptor; Macrophages; Microglia; Multiple sclerosis; Remyelination

Indexed keywords

CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7;

ADULT; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MALE; MICROGLIA; MONOCYTE; MULTIPLE SCLEROSIS; NERVE BIOPSY; PROTEIN EXPRESSION; REMISSION; REMYELINIZATION;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOPSY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MICROGLIA; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE REGENERATION; RECEPTORS, CCR5; RECEPTORS, CCR7; RECOVERY OF FUNCTION;

EID: 48349089936     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508089359     Document Type: Article

References (24)

1. Patrikios, P, Stadelmann, C, Kutzelnigg, A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165-3172.
2. Lucchinetti, C, Brück, W, Parisi, J, Scheithauer, B, Rodriguez, M, Lassmann, H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47: 707-717.
3. Arnett, HA, Wang, Y, Matsushima, GK, Suzuki, K, Ting, JP. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 2003; 23: 9824-9832.
4. Kotter, MR, Setzu, A, Sim, FJ, Van Roijen, N, Franklin, RJ. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001; 35: 204-212.
5. Kotter, MR, Zhao, C, Van Rooijen, N, Franklin, RJ. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005; 18: 166-175.
6. Li, WW, Setzu, A, Zhao, C, Franklin, RJ. Minocycline- mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J Neuroimmunol 2005; 158: S8-66.
7. Trebst, C, Sørensen, TL, Kivisäkk, P, et al. CCR1+/ CCRS+mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001; 159: 1701-1710.
8. Mahad, DJ, Trebst, C, Kivisäkk, P, et al. Expression of chemokine receptors CCR1 and CCRS reflects differential activation of mononuclear phagocytes in pattern II and III multiple sclerosis lesions. J Neuropathol Exp Neurol 2004; 63: 262-273.
9. Brück, W, Porada, P, Poser, S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38: 788-796.
10. Lucchinetti, CF, Brück, W, Rodriguez, M, Lassmann, H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-274.
11. Bück, W, Kuhlmann, T, Stadelmann, C. Remyelination in multiple sclerosis. J Neurol Sci 2003; 206: 181-185.
12. Kivisäkk, P, Mahad, DJ, Callahan, K, et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004; 55: 627-638.
13. Sørensen, TL, Tani, M, Jensen, J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-815.
14. Boven, LA, Van Meurs, M, Van Zwam, M, et al. Myelinladen macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 2006; 129: 517-526.
15. van Rossum, D, Hilbert, S, Strassenburg, S, Hanisch, UK, Bruck, W. Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype. Glia 2008; 56: 271-283.
16. Hanisch, UK, Kettenmann, H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10: 1387-1394.
17. Lai, AY, Todd, KG. Differential regulation of trophic and proinflammatory microglial effectors is dependent on severity of neuronal injury. Glia 2008; 56: 259-270.
18. Jurevics, H, Largent, C, Hostettler, J, et al. Alterations in metabolism and gene expression in brain regions during cuprizone-induced demyelination and remyelination. J Neurochem 2002; 82: 126-136.
19. McMahon, EJ, Cook, DN, Suzuki, K, Matsushima, GK. Absence of macrophage-inflammatory protein-1alpha delays central nervous system demyelination in the presence of an intact blood-brain barrier. J Immunol 2001; 167: 2964-2971.
20. Bennetts, BH, Teutsch, SM, Buhler, MM, Heard, RN, Stewart, GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58: 52-59.
21. Silversides, JA, Heggarty, SV, McDonnell, GV, Hawkins, SA, Graham, CA. Influence of CCRS delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 2004; 10: 149-152.
22. Sellebjerg, F, Madsen, HO, Jensen, CV, Jensen, J, Garred, P. CCRS delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102: 98-106.
23. Kantarci, OH, Morales, Y, Ziemer, PA, et al. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 2005; 169: 137-143.
24. Gade-Andavolu, R, Comings, DE, MacMurray, J, et al. Association of CCRS delta32 deletion with early death in multiple sclerosis. Genet Med 2004; 6: 126-131.